|Mr. John G. Melo||Pres, CEO & Director||1.94M||N/A||1966|
|Mr. Hermanus Kieftenbeld||CFO & Chief Admin. Officer||1.08M||N/A||1966|
|Mr. Eduardo Alvarez||Chief Operating Officer||1.24M||N/A||1964|
|Ms. Nicole Kelsey||Chief Legal Officer & Sec.||623.41k||N/A||1967|
|Mr. Peter DeNardo||Sr. Director of Investor Relations & Corp. Communications||N/A||N/A||N/A|
|Ms. Christine Ofori||Chief People Officer||N/A||N/A||N/A|
|Mr. Charles Kraft||Sr. VP of Global Manufacturing & Process Devel.||N/A||N/A||N/A|
|Ms. Caroline Hadfield||Pres of Aprinnova||N/A||N/A||N/A|
|Mr. Jim Iacoponi||Sr. VP of Nutrition Ingredients||N/A||N/A||N/A|
|Ms. Beth Baker Bannerman||Chief Engagement & Sustainability Officer||N/A||N/A||N/A|
Amyris, Inc., a synthetic biotechnology company, operates in the clean health and beauty, and flavors and fragrance markets in Europe, North America, Asia, and South America. The company manufactures and sells clean beauty, personal care, and health and wellness consumer products, as well as ingredients to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets. It offers its products under the Biossance, Pipette, Purecane, Terasana, Costa Brazil, OLIKA, Rose Inc., and JVN brand names. The company has a collaboration agreement with the Infectious Disease Research Institute for the development of a COVID-19 vaccine. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was incorporated in 2003 and is headquartered in Emeryville, California.
Amyris, Inc.’s ISS governance QualityScore as of 1 September 2022 is 10. The pillar scores are Audit: 9; Board: 6; Shareholder rights: 8; Compensation: 10.